AI Article Synopsis
- * Experimentation revealed that RIPerC alone improved blood flow and neurological success, while tPA alone did not lead to significant neurological improvements despite reducing infarct size.
- * Combining RIPerC with tPA resulted in even greater benefits, improving neurological outcomes and further decreasing infarct size, indicating that this combination therapy could be an effective, simple, and cost-efficient treatment option for strokes.
Article Abstract
Background And Purpose: Remote ischemic conditioning is cardioprotective in myocardial infarction and neuroprotective in mechanical occlusion models of stroke. However, there is no report on its therapeutic potential in a physiologically relevant embolic stroke model (embolic middle cerebral artery occlusion) in combination with intravenous tissue-type plasminogen activator (tPA).
Methods: We tested remote ischemic perconditioning therapy (RIPerC) at 2 hours after embolic middle cerebral artery occlusion in the mouse with and without intravenous tPA at 4 hours. We assessed cerebral blood flow up to 6 hours, neurological deficits, injury size, and phosphorylation of Akt (Serine(473)) as a prosurvival signal in the ischemic hemisphere at 48 hours poststroke.
Results: RIPerC therapy alone improved the cerebral blood flow and neurological outcomes. tPA alone at 4 hours did not significantly improve the neurological outcome even after successful thrombolysis. Individual treatments with RIPerC and intravenous tPA reduced the infarct size (25.7% and 23.8%, respectively). Combination therapy of RIPerC and tPA resulted in additive effects in further improving the neurological outcome and reducing the infarct size (50%). All the therapeutic treatments upregulated phosphorylation of Akt in the ischemic hemisphere.
Conclusions: RIPerC is effective alone after embolic middle cerebral artery occlusion and has additive effects in combination with intravenous tPA. RIPerC may be a simple, safe, and inexpensive combination therapy with intravenous tPA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740528 | PMC |
| http://dx.doi.org/10.1161/STROKEAHA.112.660373 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction Parenteral heparin is widely used as bridging therapy while optimising oral anticoagulation(OAC). Newer Direct-Acting OACs(DOACs) attain therapeutic effect very quickly. We report the use of dabigatran as bridging therapy during warfarin optimization for cardioembolic stroke in two patients who opted to receive warfarin for long-term anticoagulation for secondary stroke prevention.
View Article and Find Full Text PDFDual antiplatelet versus alteplase in anterior and posterior circulation minor stroke.
Stroke Vasc Neurol
December 2024
Department of Neurology, General Hospital of Northern Theatre Command, Shenyang, Liaoning, China
Objective: The Antiplatelet versus R-tPA for Acute Mild Ischaemic Stroke trial has demonstrated the non-inferiority of dual antiplatelet therapy (DAPT) to alteplase in minor non-disabling stroke. This prespecified secondary analysis aimed to investigate whether the treatment effects were similar across stroke territories.
Methods: Participants were divided according to stroke territory, which were subdivided into DAPT and alteplase.
Should We Switch to Tenecteplase for all Ischaemic Strokes? Evidence and Logistics.
Int J Stroke
November 2024
School of Cardiovascular & Metabolic Health, University of Glasgow Queen Elizabeth University Hospital, Glasgow G51 4TF, Scotland UK.
Recent clinical trials provide robust evidence of non-inferiority of tenecteplase 0.25mg/kg over alteplase 0.9mg/kg in acute ischaemic stroke treated within 4.
View Article and Find Full Text PDFThe role of neutrophils in tPA thrombolysis after stroke: a malicious troublemaker.
Front Immunol
November 2024
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Acute ischemic stroke represents a critical, life-threatening condition affecting the central nervous system. Intravenous thrombolysis with tissue plasminogen activator (tPA) remains a cornerstone for achieving vascular recanalization in such patients; however, its therapeutic utility is limited, with only approximately 10% of patients benefiting due to the narrow therapeutic window and significant risk of hemorrhagic transformation. Enhancing the efficacy of tPA thrombolysis is therefore imperative.
View Article and Find Full Text PDFOptimizing stent retrievers for mechanical enhancement and in vitro testing in acute ischemic stroke models.
Biomed Eng Online
November 2024
Department of Convergence Medicine, College of Medicine, Korea University, Seoul, South Korea.
Background: Acute ischemic stroke (AIS) remains a major cause of morbidity and mortality worldwide. Mechanical thrombectomy, especially with stent retrievers, offers a promising treatment, particularly for patients ineligible for intravenous tissue plasminogen activator (IV tPA) therapy. This study aimed to develop and evaluate novel stent retriever designs to enhance mechanical properties and vessel compatibility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!